See more : Halberg-Gundersen Invest – Globale Aktier (GDIGA.CO) Income Statement Analysis – Financial Results
Complete financial analysis of Tiziana Life Sciences Ltd (TLSA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tiziana Life Sciences Ltd, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Longview Tea Company Limited (LONTE.BO) Income Statement Analysis – Financial Results
- Insight Acquisition Corp. (INAQ-UN) Income Statement Analysis – Financial Results
- BTCS Inc. (BTCS) Income Statement Analysis – Financial Results
- Gravita India Limited (GRAVITA.NS) Income Statement Analysis – Financial Results
- Koninklijke DSM N.V. (DSM.AS) Income Statement Analysis – Financial Results
Tiziana Life Sciences Ltd (TLSA)
About Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K | 0.00 | -82.00K | 0.00 | 56.00K | 92.00K | 64.00K | 405.00K | 116.00K | 99.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.00K | 20.00K | 24.00K | 209.00K | 40.00K | 45.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K | 0.00 | -82.00K | 0.00 | 45.00K | 72.00K | 40.00K | 196.00K | 76.00K | 54.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 100.00% | 0.00% | 80.36% | 78.26% | 62.50% | 48.40% | 65.52% | 54.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 8.11M | 12.96M | 13.21M | 5.99M | 2.91M | 4.34M | 4.67M | 2.96M | 6.29M | 794.00K | 0.00 | 0.00 | 0.00 | 0.00 | 80.00K | 412.00K | 737.00K | 826.00K | 745.00K | 457.00K | 326.00K | 580.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 855.00K | 13.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 286.00K | 458.00K | 207.00K | 0.00 | 719.00K | 1.18M | 1.53M | 1.67M | 0.00 | 0.00 | 0.00 | 1.29M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 855.00K | 13.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 286.00K | 458.00K | 207.00K | 0.00 | 719.00K | 1.18M | 1.53M | 1.67M | 0.00 | 0.00 | 0.00 | 1.29M | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 9.87M | 1.63M | 13.31M | 8.82M | 4.86M | 3.48M | 3.57M | 4.33M | 2.33M | 1.97M | 0.00 | 0.00 | 82.00K | -3.03M | -9.00K | -2.00K | 63.00K | 0.00 | 1.50M | 1.06M | 218.00K | 451.00K | 2.42M | 2.43M | 488.00K | 199.00K |
| Operating Expenses | 17.98M | 14.59M | 27.37M | 30.04M | 7.77M | 7.82M | 8.25M | 7.29M | 8.61M | 2.76M | 286.00K | 458.00K | 289.00K | -3.03M | 790.00K | 1.59M | 2.33M | 2.50M | 2.24M | 1.52M | 544.00K | 2.32M | 2.42M | 2.43M | 488.00K | 199.00K |
| Cost & Expenses | 17.98M | 14.59M | 27.37M | 28.03M | 7.77M | 7.82M | 8.25M | 7.29M | 8.61M | 2.76M | 286.00K | 458.00K | 289.00K | -3.03M | 801.00K | 1.61M | 2.35M | 2.71M | 2.28M | 1.57M | 544.00K | 2.32M | 2.42M | 2.43M | 488.00K | 199.00K |
| Interest Income | 1.15M | 0.00 | 0.00 | 8.00K | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.00K | 56.00K | 36.00K | 47.00K | 47.00K | 10.00K | 22.00K | 79.00K | 157.00K | 8.00K | 1.00K |
| Interest Expense | 10.00K | 7.00K | 176.00K | 320.00K | 73.00K | 9.46K | 9.00K | 9.00K | 18.00K | 14.00K | 0.00 | 0.00 | 0.00 | 0.00 | 4.00K | 3.00K | 5.00K | 8.00K | 10.00K | 5.00K | 8.00K | 2.00K | 4.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 96.00K | 51.00K | 141.00K | 89.76K | 198.00K | 12.61K | 11.00K | 8.00K | 0.00 | -794.00K | 3.00K | -195.00K | -489.00K | 0.00 | 238.00K | 300.00K | 59.00K | 133.00K | 33.00K | 20.00K | 32.00K | 21.00K | 20.00K | 25.00K | 1.00K | 1.00K |
| EBITDA | -17.14M | -15.34M | -26.34M | -27.93M | -7.58M | -7.81M | -8.24M | -7.28M | -8.61M | -3.56M | -283.00K | -653.00K | -778.00K | -3.03M | -516.00K | -1.24M | -2.49M | -2.15M | -2.18M | -1.48M | -1.95M | -2.35M | -2.39M | -2.33M | -553.00K | -271.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9,433.33% | 0.00% | 948.78% | 0.00% | -921.43% | -1,348.91% | -3,890.63% | -531.60% | -1,879.31% | -1,491.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -17.98M | -14.59M | -27.37M | -28.03M | -7.77M | -7.82M | -8.25M | -7.29M | -8.61M | -2.76M | -286.00K | -458.00K | -289.00K | -3.03M | -754.00K | -1.54M | -2.55M | -2.29M | -2.21M | -1.50M | -1.98M | -2.37M | -2.41M | -2.35M | -554.00K | -272.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9,533.33% | 0.00% | 352.44% | 0.00% | -1,346.43% | -1,675.00% | -3,982.81% | -564.44% | -1,907.76% | -1,512.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 742.00K | -811.00K | 717.00K | -312.00K | -73.00K | -8.67K | -9.00K | -9.00K | -18.00K | -808.00K | 3.00K | -195.00K | 0.00 | 0.00 | -4.00K | 31.00K | -37.00K | -8.00K | -10.00K | -5.00K | -8.00K | -2.00K | -4.00K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -17.24M | -15.40M | -26.66M | -28.34M | -7.85M | -7.83M | -8.26M | -7.30M | -8.63M | -3.57M | -283.00K | -653.00K | -289.00K | 0.00 | -758.00K | -1.51M | -2.59M | -2.29M | -2.22M | -1.50M | -1.99M | -2.37M | -2.41M | -2.35M | -554.00K | -272.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9,433.33% | 0.00% | 352.44% | 0.00% | -1,353.57% | -1,641.30% | -4,040.63% | -566.42% | -1,916.38% | -1,517.17% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 449.00K | 0.00 | -3.24M | -2.21M | -540.00K | -1.53M | -1.49M | -89.00K | 0.00 | -60.00K | -3.00K | 195.00K | 489.00K | 3.03M | -28.00K | -81.00K | -169.00K | -118.00K | -82.00K | -114.00K | -30.00K | -65.00K | -89.00K | -83.00K | 0.00 | 0.00 |
| Net Income | -17.69M | -15.40M | -23.42M | -26.13M | -7.31M | -6.30M | -6.77M | -7.21M | -8.63M | -3.51M | -280.00K | -848.00K | -778.00K | -3.03M | -730.00K | -1.43M | -2.42M | -2.18M | -2.14M | -1.39M | -1.96M | -2.31M | -2.33M | -2.27M | -554.00K | -272.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9,333.33% | 0.00% | 948.78% | 0.00% | -1,303.57% | -1,553.26% | -3,776.56% | -537.28% | -1,845.69% | -1,402.02% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | -0.15 | -0.24 | -0.27 | -0.05 | -0.10 | -0.13 | -0.15 | -0.19 | -0.31 | 0.00 | 0.00 | 0.00 | -0.10 | -0.05 | -0.24 | -0.52 | -0.01 | -0.01 | -0.01 | -0.02 | -0.06 | -0.09 | -0.09 | -0.02 | -0.01 |
| EPS Diluted | 0.00 | -0.15 | -0.24 | -0.27 | -0.05 | -0.10 | -0.13 | -0.15 | -0.19 | -0.31 | 0.00 | 0.00 | 0.00 | -0.10 | -0.05 | -0.24 | -0.52 | -0.01 | -0.01 | -0.01 | -0.02 | -0.06 | -0.09 | -0.09 | -0.02 | -0.01 |
| Weighted Avg Shares Out | 0.00 | 101.53M | 97.93M | 97.31M | 136.48M | 63.78M | 53.20M | 46.80M | 45.62M | 11.43M | 273.43M | 214.38M | 179.12M | 31.08M | 13.67M | 5.96M | 4.64M | 297.60M | 191.67M | 140.37M | 100.40M | 37.75M | 25.07M | 24.09M | 25.77M | 25.77M |
| Weighted Avg Shares Out (Dil) | 0.00 | 101.53M | 97.93M | 97.31M | 136.48M | 63.78M | 53.20M | 46.80M | 45.62M | 11.43M | 273.43M | 214.38M | 179.12M | 31.08M | 13.67M | 5.96M | 4.64M | 297.60M | 191.67M | 140.37M | 100.40M | 37.75M | 25.07M | 24.09M | 25.77M | 25.77M |
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced “first patient dosed” in its Phase 2a study comparing two doses of intranasal foralumab...
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that Matthew Davis, Chief Operating Officer and Chief...
Tiziana Life Sciences advances multiple sclerosis research program with enrollment and dosing of patients
Biotechnology firm Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it had successfully enrolled and dosed four new patients with non-active secondary progressive multiple sclerosis (na-SPMS) in the Brigham and Women's Hospital, a key member of the Mass General Brigham Healthcare System...
Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
NEW YORK, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the company has successfully enrolled and dosed...
Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that its Chief Operating Officer and Chief Medical...
Tiziana Life Sciences: FDA signs off on home-based protocol fo MS treatment
Regulators have granted approval for home-based self-administration of Intranasal Foralumab, a treatment developed by Tiziana Life Sciences Ltd (NASDAQ:TLSA). Sign-off by the US Food & Drug Administration for this approach marks a major step forward in making treatment more accessible and convenient...
Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment
NEW YORK, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce a significant milestone in the...
Tiziana Life Sciences stock continues to climb; COO ‘excited' by recent results
Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares rose 8% to $0.86 in midday trading on Monday after the clinical-stage biopharmaceutical company revealed six-month data that showed positive clinical improvements related to Modified Fatigue Impact Scale (MFIS) scores and similar important clinical...
Tiziana Life Sciences reveals positive clinical results for MS patients treated with Foralumab
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced six-month data showing positive clinical improvements related to Modified Fatigue Impact Scale (MFIS) scores and similar important clinical measures of physical function in foralumab-treated, non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients participating in...
Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab
NEW YORK, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced six-month data showing positive clinical improvements related to...
Source: https://incomestatements.info
Category: Stock Reports